Status:
UNKNOWN
Ranolazine for Improving Symptoms of Palpitations
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Ischemic Heart Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Patients with ischemic heart disease often report multiple symptoms, including angina and palpitations. Ranolazine has antiarrhythmic effects which are largely a result of the drug's effect on multipl...
Detailed Description
Background: Patients with ischemic heart disease often report multiple symptoms, including angina and palpitations. Ranolazine is a novel antianginal and antiischemic drug that reduces intracellular...
Eligibility Criteria
Inclusion
- Symptoms of palpitations
- Angiographically-proven coronary artery disease
- Stable conditions
- No recent acute coronary syndromes
- Able to understand and willing to sign the informed consent form
- Symptomatic patients (palpitation) with stable angina pectoris already on therapy with beta-blockers and/or calcium antagonists.
Exclusion
- Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours
- Severe renal failure
- Severe hepatic failure
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01495520
Start Date
January 1 2014
End Date
December 1 2016
Last Update
March 7 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.